Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GLAXO.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GLAXO.BO and 80,000+ other tickers.
See exactly how GLAXO.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GLAXO.BO and 80,000+ other tickers.
GlaxoSmithKline Pharmaceuticals Limited is a prominent pharmaceutical company involved in the manufacturing, distribution, and sale of medicines across India and internationally. Its extensive product portfolio includes a range of vital vaccines: Infanrix Hexa, for infant protection against six diseases including diphtheria, tetanus, and hepatitis B; Synflorix, for pneumococcal infections and acute otitis media; Havrix, preventing Hepatitis A; Menveo, targeting invasive meningococcal disease; Boostrix, for diphtheria, tetanus, and pertussis; Fluarix Tetra, for influenza prevention; Varilrix…
No recent news available.